世界の希少疾患市場2026:インサイト・予測

QYResearchが発行した調査報告書(QYR20NV04096)
◆英語タイトル:Global Orphan Diseases Market Size, Status and Forecast 2020-2026
◆商品コード:QYR20NV04096
◆発行会社(リサーチ会社):QYResearch
◆発行日:2020年11月(※2024年版があります。お問い合わせください。)
◆ページ数:97
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆産業分野:ヘルスケア
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,900 ⇒換算¥577,200見積依頼/購入/質問フォーム
Multi User(5名様閲覧用)USD5,850 ⇒換算¥865,800見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD7,800 ⇒換算¥1,154,400見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はQYResearch社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。QYResearch社の概要及び新刊レポートはこちらでご確認いただけます。

本調査レポートは希少疾患の世界市場について調査・分析した資料です。種類別(自己免疫疾患、遺伝性疾患、血液疾患、癌、成長障害、心血管疾患、神経障害、呼吸器疾患、消化器疾患、眼疾患)の市場規模、用途別(病院・診療所、研究所)の市場規模、地域別(北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等)の市場規模データ、主な企業情報と企業別市場シェア等が記載されています。
・調査範囲
・エグゼクティブサマリー
・企業別希少疾患の競争状況、市場シェア
・世界の希少疾患市場:種類別市場規模 2015年-2020年(自己免疫疾患、遺伝性疾患、血液疾患、癌、成長障害、心血管疾患、神経障害、呼吸器疾患、消化器疾患、眼疾患)
・世界の希少疾患市場:種類別市場規模予測 2021年-2026年(自己免疫疾患、遺伝性疾患、血液疾患、癌、成長障害、心血管疾患、神経障害、呼吸器疾患、消化器疾患、眼疾患)
・世界の希少疾患市場:用途別市場規模 2015年-2020年(病院・診療所、研究所)
・世界の希少疾患市場:用途別市場規模予測 2021年-2026年(病院・診療所、研究所)
・北米の希少疾患市場分析:米国、カナダ
・ヨーロッパの希少疾患市場分析:ドイツ、フランス、イギリス、イタリア、ロシア等
・アジアの希少疾患市場分析:日本、中国、韓国、インド、オーストラリア、台湾等
・中南米の希少疾患市場分析:メキシコ、ブラジル、アルゼンチン等
・中東・アフリカの希少疾患市場分析:トルコ、サウジアラビア、UAE等
・企業情報(企業概要、製品概要、販売量、企業動向)
- 掲載企業(変更可能性あり):Bristol-Myers Squibb、Novartis、Celgene、Roche、Pfizer、Alexion、Sanofi、Vertex Pharmaceuticals、GlaxoSmithKline、Merck、Abbvie
・地域別市場規模予測(2021年-2026年):北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場
・市場機会、課題、リスク、環境分析
・バリューチェーン、販売チャネル分析
・調査の結論
【レポートの概要】

An orphan disease is defined as a condition that affects fewer than 200,000 people nationwide. This includes diseases as familiar as cystic fibrosis, Lou Gehrig’s disease, and Tourette’s syndrome, and as unfamiliar as Hamburger disease, Job syndrome, and acromegaly, or “gigantism.” Some diseases have patient populations of fewer than a hundred.
New rare diseases are discovered every year. Most are inherited and caused by alterations or defects in genes (mutations). Others can be acquired as a result of environmental and toxic conditions. Genes are pieces of DNA, part of the code that determines the traits and individual characteristics of all living things.

Market Analysis and Insights: Global Orphan Diseases Market
The global Orphan Diseases market size is projected to reach US$ 268.4 million by 2026, from US$ 233.7 million in 2020, at a CAGR of 14.1%% during 2021-2026.

Global Orphan Diseases Scope and Market Size
Orphan Diseases market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Orphan Diseases market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

The key players covered in this study
Bristol-Myers Squibb
Novartis
Celgene
Roche
Pfizer
Alexion
Sanofi
Vertex Pharmaceuticals
GlaxoSmithKline
Merck
Abbvie

Market segment by Type, the product can be split into
Autoimmune Disorders
Genetic Disorders
Blood Disorders
Cancer
Growth Disorder
Cardiovascular Diseases
Neurological Disorders
Respiratory Disorders
Digestive Disorders
Eye Disorders
Market segment by Application, split into
Hospitals And Clinics
Research Laboratories

Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India

【レポートの目次】

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Orphan Diseases Revenue
1.4 Market by Type
1.4.1 Global Orphan Diseases Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Autoimmune Disorders
1.4.3 Genetic Disorders
1.4.4 Blood Disorders
1.4.5 Cancer
1.4.6 Growth Disorder
1.4.7 Cardiovascular Diseases
1.4.8 Neurological Disorders
1.4.9 Respiratory Disorders
1.4.10 Digestive Disorders
1.4.11 Eye Disorders
1.5 Market by Application
1.5.1 Global Orphan Diseases Market Share by Application: 2020 VS 2026
1.5.2 Hospitals And Clinics
1.5.3 Research Laboratories
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Global Orphan Diseases Market Perspective (2015-2026)
2.2 Global Orphan Diseases Growth Trends by Regions
2.2.1 Orphan Diseases Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Orphan Diseases Historic Market Share by Regions (2015-2020)
2.2.3 Orphan Diseases Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Orphan Diseases Market Growth Strategy
2.3.6 Primary Interviews with Key Orphan Diseases Players (Opinion Leaders)

3 Competition Landscape by Key Players
3.1 Global Top Orphan Diseases Players by Market Size
3.1.1 Global Top Orphan Diseases Players by Revenue (2015-2020)
3.1.2 Global Orphan Diseases Revenue Market Share by Players (2015-2020)
3.1.3 Global Orphan Diseases Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Orphan Diseases Market Concentration Ratio
3.2.1 Global Orphan Diseases Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Orphan Diseases Revenue in 2019
3.3 Orphan Diseases Key Players Head office and Area Served
3.4 Key Players Orphan Diseases Product Solution and Service
3.5 Date of Enter into Orphan Diseases Market
3.6 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)
4.1 Global Orphan Diseases Historic Market Size by Type (2015-2020)
4.2 Global Orphan Diseases Forecasted Market Size by Type (2021-2026)

5 Market Size by Application (2015-2026)
5.1 Global Orphan Diseases Market Size by Application (2015-2020)
5.2 Global Orphan Diseases Forecasted Market Size by Application (2021-2026)

6 North America
6.1 North America Orphan Diseases Market Size (2015-2020)
6.2 Orphan Diseases Key Players in North America (2019-2020)
6.3 North America Orphan Diseases Market Size by Type (2015-2020)
6.4 North America Orphan Diseases Market Size by Application (2015-2020)

7 Europe
7.1 Europe Orphan Diseases Market Size (2015-2020)
7.2 Orphan Diseases Key Players in Europe (2019-2020)
7.3 Europe Orphan Diseases Market Size by Type (2015-2020)
7.4 Europe Orphan Diseases Market Size by Application (2015-2020)

8 China
8.1 China Orphan Diseases Market Size (2015-2020)
8.2 Orphan Diseases Key Players in China (2019-2020)
8.3 China Orphan Diseases Market Size by Type (2015-2020)
8.4 China Orphan Diseases Market Size by Application (2015-2020)

9 Japan
9.1 Japan Orphan Diseases Market Size (2015-2020)
9.2 Orphan Diseases Key Players in Japan (2019-2020)
9.3 Japan Orphan Diseases Market Size by Type (2015-2020)
9.4 Japan Orphan Diseases Market Size by Application (2015-2020)

10 Southeast Asia
10.1 Southeast Asia Orphan Diseases Market Size (2015-2020)
10.2 Orphan Diseases Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Orphan Diseases Market Size by Type (2015-2020)
10.4 Southeast Asia Orphan Diseases Market Size by Application (2015-2020)

11 India
11.1 India Orphan Diseases Market Size (2015-2020)
11.2 Orphan Diseases Key Players in India (2019-2020)
11.3 India Orphan Diseases Market Size by Type (2015-2020)
11.4 India Orphan Diseases Market Size by Application (2015-2020)

12 Central & South America
12.1 Central & South America Orphan Diseases Market Size (2015-2020)
12.2 Orphan Diseases Key Players in Central & South America (2019-2020)
12.3 Central & South America Orphan Diseases Market Size by Type (2015-2020)
12.4 Central & South America Orphan Diseases Market Size by Application (2015-2020)

13 Key Players Profiles
13.1 Bristol-Myers Squibb
13.1.1 Bristol-Myers Squibb Company Details
13.1.2 Bristol-Myers Squibb Business Overview
13.1.3 Bristol-Myers Squibb Orphan Diseases Introduction
13.1.4 Bristol-Myers Squibb Revenue in Orphan Diseases Business (2015-2020))
13.1.5 Bristol-Myers Squibb Recent Development
13.2 Novartis
13.2.1 Novartis Company Details
13.2.2 Novartis Business Overview
13.2.3 Novartis Orphan Diseases Introduction
13.2.4 Novartis Revenue in Orphan Diseases Business (2015-2020)
13.2.5 Novartis Recent Development
13.3 Celgene
13.3.1 Celgene Company Details
13.3.2 Celgene Business Overview
13.3.3 Celgene Orphan Diseases Introduction
13.3.4 Celgene Revenue in Orphan Diseases Business (2015-2020)
13.3.5 Celgene Recent Development
13.4 Roche
13.4.1 Roche Company Details
13.4.2 Roche Business Overview
13.4.3 Roche Orphan Diseases Introduction
13.4.4 Roche Revenue in Orphan Diseases Business (2015-2020)
13.4.5 Roche Recent Development
13.5 Pfizer
13.5.1 Pfizer Company Details
13.5.2 Pfizer Business Overview
13.5.3 Pfizer Orphan Diseases Introduction
13.5.4 Pfizer Revenue in Orphan Diseases Business (2015-2020)
13.5.5 Pfizer Recent Development
13.6 Alexion
13.6.1 Alexion Company Details
13.6.2 Alexion Business Overview
13.6.3 Alexion Orphan Diseases Introduction
13.6.4 Alexion Revenue in Orphan Diseases Business (2015-2020)
13.6.5 Alexion Recent Development
13.7 Sanofi
13.7.1 Sanofi Company Details
13.7.2 Sanofi Business Overview
13.7.3 Sanofi Orphan Diseases Introduction
13.7.4 Sanofi Revenue in Orphan Diseases Business (2015-2020)
13.7.5 Sanofi Recent Development
13.8 Vertex Pharmaceuticals
13.8.1 Vertex Pharmaceuticals Company Details
13.8.2 Vertex Pharmaceuticals Business Overview
13.8.3 Vertex Pharmaceuticals Orphan Diseases Introduction
13.8.4 Vertex Pharmaceuticals Revenue in Orphan Diseases Business (2015-2020)
13.8.5 Vertex Pharmaceuticals Recent Development
13.9 GlaxoSmithKline
13.9.1 GlaxoSmithKline Company Details
13.9.2 GlaxoSmithKline Business Overview
13.9.3 GlaxoSmithKline Orphan Diseases Introduction
13.9.4 GlaxoSmithKline Revenue in Orphan Diseases Business (2015-2020)
13.9.5 GlaxoSmithKline Recent Development
13.10 Merck
13.10.1 Merck Company Details
13.10.2 Merck Business Overview
13.10.3 Merck Orphan Diseases Introduction
13.10.4 Merck Revenue in Orphan Diseases Business (2015-2020)
13.10.5 Merck Recent Development
13.11 Abbvie
10.11.1 Abbvie Company Details
10.11.2 Abbvie Business Overview
10.11.3 Abbvie Orphan Diseases Introduction
10.11.4 Abbvie Revenue in Orphan Diseases Business (2015-2020)
10.11.5 Abbvie Recent Development

14 Analyst’s Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details

...

【掲載企業】

Bristol-Myers Squibb、Novartis、Celgene、Roche、Pfizer、Alexion、Sanofi、Vertex Pharmaceuticals、GlaxoSmithKline、Merck、Abbvie

【免責事項】
https://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界の希少疾患市場2026:インサイト・予測(Global Orphan Diseases Market Size, Status and Forecast 2020-2026)]についてメールでお問い合わせはこちらでお願いします。